LSTA Q3 2025 Earnings — Lisata Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

LSTALisata Therapeutics, Inc.

$44M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$4M

Net Income

-$4M

EPS (Diluted)

$-0.49

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$232,000

Balance Sheet

Total Assets

$22M

Total Liabilities

$5M

Stockholders' Equity

$17M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$4M	-$5M	+17.3%
Net Income	-$4M	-$5M	+13.8%